MedTrace Logo

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

NCT00130039 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 457

Last updated 2010-01-12

Study results available
· View outcomes & findings →

Summary

This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery).

They will be randomly assigned into cilostazol group or clopidogrel group. Every patients will take 100mg of aspirin a day additionally.

The primary outcome variable of this study is Progression rate of symptomatic intracranial stenosis on magnetic resonance angiogram (MRA).

Conditions

Interventions

DRUG

clopidogrel

Clopidogrel 75mg once a day plus placebo of cilostazol twice a day

DRUG

Cilostazol

Cilostazol 100mg twice a day plus placebo of clopidogrel once a day

Sponsors & Collaborators

  • Korea Otsuka International Asia Arab

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Sun U. Kwon, MD, PhD · Asan Medical Center, Univsersity of Ulsan, Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Hong Kong
  • Philippines
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130039 on ClinicalTrials.gov